Vivos Inc (RDGL)

[AtlasQ]

### Comparison of Point Biopharma and Vivos Inc. (Radiogel) Products

**Point Biopharma:**

1. **Overview:**
Point Biopharma is a radiopharmaceutical company specializing in radioligand therapies, which combine a radioactive isotope with a targeting molecule to deliver radiation directly to cancer cells. This approach aims to minimize damage to healthy tissues compared to traditional chemotherapy.

2. **Key Products and Pipeline:**
- **PNT2002**: A prostate-specific membrane antigen (PSMA)-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). The Phase 3 SPLASH trial showed significant improvement in radiographic progression-free survival compared to control treatments [oai_citation:1,Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | Eli Lilly and Company](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next) [oai_citation:2,Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/148602-lantheus-and-point-biopharma-announce-positive-topline-results-from-pivotal-splash-trial-in-metastatic-castration-resistant-prostate-cancer.html).
- **PNT2003**: A somatostatin receptor-targeted therapy for neuroendocrine tumors.
- **PNT2004**: Targets fibroblast activation protein-alpha (FAP-a), present in over 90% of solid tumors. It has potential as a monotherapy or in combination with other treatments [oai_citation:3,POINT Biopharma Provides Early-Stage Program Updates](https://www.globenewswire.com/news-release/2022/02/14/2384407/0/en/POINT-Biopharma-Provides-Early-Stage-Program-Updates.html).

3. **Technology and Manufacturing:**
- Point has established a vertically integrated platform, ensuring control over the development, manufacturing, and delivery of radiopharmaceuticals. This includes securing supplies of critical isotopes like actinium-225 and lutetium-177 [oai_citation:4,Creating the platform for next-generation radiopharmaceuticals](https://www.nature.com/articles/d43747-022-00052-2).
- The company’s Indianapolis facility is capable of serving North America and beyond, allowing for on-demand manufacturing and rapid distribution to clinics [oai_citation:5,Creating the platform for next-generation radiopharmaceuticals](https://www.nature.com/articles/d43747-022-00052-2).

**Vivos Inc. (Radiogel):**

1. **Overview:**
Vivos Inc. develops Radiogel, a minimally invasive injectable treatment designed to deliver high-dose radiation directly to cancerous tissues. The product uses a water-based gel to encapsulate radioactive particles, allowing for localized radiation therapy.

2. **Key Products and Pipeline:**
- **Radiogel™**: An injectable hydrogel that delivers yttrium-90, a beta-emitting radioisotope, directly into tumors. This method aims to provide precise radiation therapy with minimal exposure to surrounding healthy tissues.
- **IsoPet®**: A veterinary version of Radiogel, used for treating solid tumors in animals.

3. **Technology and Manufacturing:**
- Radiogel is designed to be a highly localized treatment option, reducing the need for extensive systemic radiation therapy. It is particularly suited for solid tumors where precise radiation delivery is crucial.
- The product leverages the physical properties of hydrogels to retain the radioactive isotopes at the tumor site, thus minimizing the spread of radiation to other body parts.

### Summary:
- **Point Biopharma** focuses on radioligand therapies, using isotopes like lutetium-177 and actinium-225 to treat various cancers, with a strong emphasis on precision targeting and minimizing side effects. Their advanced manufacturing capabilities support rapid production and distribution.
- **Vivos Inc.'s Radiogel** provides a localized radiation therapy option through injectable hydrogels, focusing on delivering high-dose radiation directly to tumors while sparing healthy tissues. It is currently available in both human and veterinary versions.

Both companies represent innovative approaches in the field of radiopharmaceuticals, aiming to improve the precision and effectiveness of cancer treatments while reducing adverse effects.